Therapeutic Response

MSI-H status confers therapeutic sensitivity to Pembrolizumab in patients with Any solid tumor.

Statements

Source and description
Keytruda (pembrolizumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
Keytruda (pembrolizumab) [product monograph]. HC.